Reevaluation of the role of HDL   in the anticoagulant activated   protein C system in humans.
HDL has anti-atherogenic properties, and plasma levels of HDL cholesterol correlate inversely with risk of coronary artery disease. HDL reportedly functions as a cofactor to the anticoagulant activated protein C (APC) in the degradation of factor Va (FVa). The aim of the present study was to elucidate the mechanism by which HDL functions as cofactor to APC. Consistent with a previous report, HDL isolated from human plasma by ultracentrifugation was found to stimulate APC-mediated degradation of FVa. However, further purification of HDL by gel filtration revealed that the stimulating activity was not a property of HDL. Instead, the stimulating activity eluted completely separately from HDL in the high-molecular-weight void volume fractions. The active portion of these fractions stimulated FVa degradation by APC and supported the assembly of factor Xa and FVa into a functional prothrombinase complex. Both the procoagulant and anticoagulant activities were blocked by addition of annexin V, suggesting that the active portion was negatively charged phospholipid membranes. These results demonstrate that HDL does not stimulate the APC/protein S effect and that the activity previously reported to be a property of HDL is instead caused by contaminating negatively charged phospholipid membranes.
Oslakovic
Cecilia
C
Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital, Malmö, Sweden.
Norstrøm
Eva
E
Dahlbäck
Björn
B
D017304:Annexin A5 / Q000378:metabolism; D000925:Anticoagulants / Q000378:metabolism*; D001777:Blood Coagulation; D002850:Chromatography, Gel; D015943:Factor Va / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D007700:Kinetics; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008081:Liposomes / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D011486:Protein C / Q000378:metabolism*; D013925:Thromboplastin / Q000378:metabolism
D017304:Annexin A5; D000925:Anticoagulants; D008075:Lipoproteins, HDL; D008081:Liposomes; D010743:Phospholipids; D011486:Protein C; D015943:Factor Va; D013925:Thromboplastin; D015951:Factor Xa
Circulation. 1989 Jan;79(1):8-15
2642759
J Intern Med. 2005 Mar;257(3):209-23
15715678
Am J Med. 1977 May;62(5):707-14
193398
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):12-9
16269660
J Biol Chem. 2009 Feb 27;284(9):5896-904
19129179
Blood. 1991 Jun 15;77(12):2641-8
2043766
J Am Chem Soc. 2004 Mar 24;126(11):3477-87
15025475
J Biol Chem. 1994 Dec 16;269(50):31869-80
7989361
Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1835-41
10894826
Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):458-65
9514415
Trends Cardiovasc Med. 1999 Oct;9(7):185-92
10881749
Methods Enzymol. 1993;222:260-80
8412798
J Biol Chem. 1980 Jun 25;255(12):5521-4
6892911
J Clin Invest. 1980 Sep;66(3):583-91
7400329
Curr Opin Cardiol. 2008 Jul;23(4):370-8
18520722
J Biol Chem. 2007 Aug 24;282(34):25123-30
17604270
FEBS Lett. 2005 Jun 13;579(15):3310-6
15943976
J Biol Chem. 1990 Mar 25;265(9):4923-8
2138622
Biochemistry (Mosc). 2002 Jan;67(1):3-12
11841335
Thromb Res. 2008;122 Suppl 1:S23-6
18691494
Methods Enzymol. 1986;128:70-143
3523143
Br Med Bull. 1994 Oct;50(4):813-32
7804733
Pathophysiol Haemost Thromb. 2006;35(3-4):281-91
16877877
J Thromb Haemost. 2005 Dec;3(12):2633-48
16129023
J Clin Invest. 1999 Jan;103(2):219-27
9916134
Biochemistry. 1997 Dec 23;36(51):16025-31
9440875